Non-hyperglycemic obese and overweight patients who took any of three doses of canagliflozin lost more weight and attained modest BMI reductions compared with those in the placebo group, according to a study in the journal Obesity. However, researchers did not observe significant differences in triglycerides or HDL cholesterol between the groups.

Related Summaries